Gene therapy with endogenous inhibitors of angiogenesis for neovascular age-related macular degeneration: Beyond anti-VEGF therapy

Journal of Ophthalmology

Volumn 2015, Issue , 2015, Pages

  Prea, Selwyn M ^a,b   Chan, Elsa C ^a,b   Dusting, Gregory J ^a,b   Vingrys, Algis J ^a   Bui, Bang V ^a   Liu, Guei Sheung ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CENTRE FOR EYE RESEARCH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925321774     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2015/201726     Document Type: Review

References (115)

1. T. Wong, U. Chakravarthy, R. Klein et al., "The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis," Ophthalmology, vol. 115, no. 1, pp. 116-126, 2008.
2. L. S. Lim, P. Mitchell, J. M. Seddon, F. G. Holz, and T. Y. Wong, "Age-related macular degeneration," The Lancet, vol. 379, no. 9827, pp. 1728-1738, 2012.
3. I. Bhutto and G. Lutty, "Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex," Molecular Aspects of Medicine, vol. 33, no. 4, pp. 295-317, 2012.
4. D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration," The New England Journal of Medicine, vol. 364, no. 20, pp. 1897-1908, 2011.
5. T. Y. Wong, G. Liew, and P. Mitchell, "Clinical update: new treatments for age-related macular degeneration," The Lancet, vol. 370, no. 9583, pp. 204-206, 2007.
6. U. Schmidt-Erfurth, P. K. Kaiser, J.-F. Korobelnik et al., "Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies," Ophthalmology, vol. 121, no. 1, pp. 193-201, 2014.
7. L. H. Curtis, B.G. Hammill, K. A. Schulman, and S.W. Cousins, "Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-relatedmacular degeneration," Archives of Ophthalmology, vol. 128, no. 10, pp. 1273-1279, 2010.
8. L. S. Lim, C. M. G. Cheung, P. Mitchell, and T. Y. Wong, "Emerging evidence concerning systemic safety of anti-VEGF agents-should ophthalmologists be concerned?" American Journal of Ophthalmology, vol. 152, no. 3, pp. 329-331, 2011.
9. D. F. Martin, M. G. Maguire, S. L. Fine et al., "Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results," Ophthalmology, vol. 119, no. 7, pp. 1388-1398, 2012.
10. D. M. Lipinski, M. Thake, and R. E. MacLaren, "Clinical applications of retinal gene therapy," Progress in Retinal and Eye Research, vol. 32, no. 1, pp. 22-47, 2013.
11. J. W. Bainbridge, A. J. Smith, S. S. Barker et al., "Effect of gene therapy on visual function in Leber's congenital amaurosis," The New England Journal of Medicine, vol. 358, no. 21, pp. 2231-2239, 2008.
12. S. E. Boye, S. L. Boye, A. S. Lewin, and W. W. Hauswirth, "A comprehensive review of retinal gene therapy," Molecular Therapy, vol. 21, no. 3, pp. 509-519, 2013.
13. K. Mancuso, W. W. Hauswirth, Q. Li et al., "Gene therapy for red-green colour blindness in adult primates," Nature, vol. 461, no. 7265, pp. 784-787, 2009.
14. P. Pechan, H. Rubin, M. Lukason et al., "Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization," Gene Therapy, vol. 16, no. 1, pp. 10-16, 2009.
15. M. Lukason, E. Dufresne, H. Rubin et al., "Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule," Molecular Therapy, vol. 19, no. 2, pp. 260-265, 2011.
16. K. S. Balaggan, K. Binley, M. Esapa et al., "EIAV vectormediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV," Gene Therapy, vol. 13, no. 15, pp. 1153-1165, 2006.
17. T. Takahashi, T. Nakamura, A. Hayashi et al., "Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells," The American Journal of Ophthalmology, vol. 130, no. 6, pp. 774-781, 2000.
18. B. J. Raisler, K. I. Berns, M. B. Grant, D. Beliaev, and W. W. Hauswirth, "Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization," Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 13, pp. 8909-8914, 2002.
19. P. A. Campochiaro, "Gene transfer for ocular neovascularization and macular edema," Gene Therapy, vol. 19, no. 2, pp. 121-126, 2012.
20. S. X. Zhang and J.-X. Ma, "Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy," Progress in Retinal and Eye Research, vol. 26, no. 1, pp. 1-37, 2007.
21. P.A. Campochiaro, Q.D. Nguyen, S. M. Shah et al., "Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial," Human Gene Therapy, vol. 17, no. 2, pp. 167-176, 2006.
22. S.-J. Sheu, L.-C. Chou, Y.-S. Bee et al., "Suppression of choroidal neovascularization by intramuscular polymer-based gene delivery of vasostatin," Experimental Eye Research, vol. 81, no. 6, pp. 673-679, 2005.
23. D. Zhang, P. L. Kaufman, G. Gao, R. A. Saunders, and J.-X. Ma, "Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats," Diabetologia, vol. 44, no. 6, pp. 757-765, 2001.
24. S. Wang, C. M. Sorenson, and N. Sheibani, "Lack of thrombospondin 1 and exacerbation of choroidal neovascularization," Archives of Ophthalmology, vol. 130, no. 5, pp. 615-620, 2012.
25. C. N. Graymore, "Metabolic survival of the isolated retina," British Medical Bulletin, vol. 26, no. 2, pp. 130-133, 1970.
26. J. M. Seddon, "Genetic and environmental underpinnings to age-related ocular diseases," Investigative Ophthalmology & Visual Science, vol. 54, no. 14, pp. ORSF28-ORSF30, 2013.
27. L. G. Fritsche, R. N. Fariss, D. Stambolian, G. R. Abecasis, C. A. Curcio, and A. Swaroop, "Age-related macular degeneration: genetics and biology coming together," Annual Review of Genomics and Human Genetics, vol. 15, pp. 151-171, 2014.
28. A. C. Bird, "Therapeutic targets in age-related macular disease," The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3033-3041, 2010.
29. S. Cordeiro, S. Seyler, J. Stindl, V. M. Milenkovic, and O. Strauss, "Heat-sensitive TRPV channels in retinal pigment epithelial cells: regulation of VEGF-A secretion," Investigative Ophthalmology & Visual Science, vol. 51, no. 11, pp. 6001-6008, 2010.
30. D. Bok, "The retinal pigment epithelium: a versatile partner in vision," Journal of Cell Science, vol. 106, no. 17, pp. 189-195, 1993.
31. R. H. Steinberg, R. A. Linsenmeier, and E. R. Griff, "Three lightevoked responses of the retinal pigment epithelium," Vision Research, vol. 23, no. 11, pp. 1315-1323, 1983.
32. S. S. Miller and R. H. Steinberg, "Active transport of ions across frog retinal pigment epithelium," Experimental Eye Research, vol. 25, no. 3, pp. 235-248, 1977.
33. Y. Ban and L. J. Rizzolo, "Regulation of glucose transporters during development of the retinal pigment epithelium," Developmental Brain Research, vol. 121, no. 1, pp. 89-95, 2000.
34. J. G. Hollyfield, V. L. Bonilha, M. E. Rayborn et al., "Oxidative damage-induced inflammation initiates age-related macular degeneration," Nature Medicine, vol. 14, no. 2, pp. 194-198, 2008.
35. H. F. Dvorak, L. F. Brown, M. Detmar, and A. M. Dvorak, "Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis," The American Journal of Pathology, vol. 146, no. 5, pp. 1029-1039, 1995.
36. I. Kim, A. M. Ryan, R. Rohan et al., "Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes," Investigative Ophthalmology & Visual Science, vol. 40, no. 9, pp. 2115-2121, 1999.
37. A. K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh, "VEGF receptor signalling-in control of vascular function," Nature Reviews Molecular Cell Biology, vol. 7, no. 5, pp. 359-371, 2006.
38. H. E. Grossniklaus, J. X. Ling, T. M. Wallace et al., "Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization," Molecular Vision, vol. 8, pp. 119-126, 2002.
39. D. H. Anderson, M. J. Radeke, N. B. Gallo et al., "The pivotal role of the complement systemin aging and age-relatedmacular degeneration: hypothesis re-visited," Progress in Retinal and Eye Research, vol. 29, no. 2, pp. 95-112, 2010.
40. R. F. Mullins, S. R. Russell, D. H. Anderson, and G. S. Hageman, "Drusen associated with aging and age-relatedmacular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease," The FASEB Journal, vol. 14, no. 7, pp. 835-846, 2000.
41. M. Nozaki, B. J. Raisler, E. Sakurai et al., "Drusen complement components C3a and C5a promote choroidal neovascularization," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2328-2333, 2006.
42. J. M. Thurman, B. Renner, K. Kunchithapauthamet al., "Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury," The Journal of Biological Chemistry, vol. 284, no. 25, pp. 16939-16947, 2009.
43. S. Cherepanoff, P. McMenamin, M. C. Gillies, E. Kettle, and S. H. Sarks, "Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration," British Journal of Ophthalmology, vol. 94, no. 7, pp. 918-925, 2010.
44. J. Ambati, A. Anand, S. Fernandez et al., "An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice," Nature Medicine, vol. 9, no. 11, pp. 1390-1397, 2003.
45. D. G. Espinosa-Heidmann, I. J. Suner, E. P. Hernandez, D. Monroy, K. G. Csaky, and S. W. Cousins, "Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization," Investigative Ophthalmology and Visual Science, vol. 44, no. 8, pp. 3586-3592, 2003.
46. C. Combadière, C. Feumi, W. Raoul et al., "CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration," Journal of Clinical Investigation, vol. 117, no. 10, pp. 2920-2928, 2007.
47. P. L. Penfold, S. C. K. Liew, M. C. Madigan, and J. M. Provis, "Modulation of major histocompatibility complex class II expression in retinas with age-related macular degeneration," Investigative Ophthalmology and Visual Science, vol. 38, no. 10, pp. 2125-2133, 1997.
48. D. G. Espinosa-Heidmann, M. A. Reinoso, Y. Pina, K. G. Csaky, A. Caicedo, and S. W. Cousins, "Quantitative enumeration of vascular smoothmuscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization," Experimental Eye Research, vol. 80, no. 3, pp. 369-378, 2005.
49. J. L. Kovach, S. G. Schwartz, H. W. Flynn, and I. U. Scott, "Anti-VEGF treatment strategies for wet AMD," Journal of Ophthalmology, vol. 2012, Article ID 786870, 7 pages, 2012.
50. D. R. Lally, A. T. Gerstenblith, and C. D. Regillo, "Preferred therapies for neovascular age-related macular degeneration," Current Opinion in Ophthalmology, vol. 23, no. 3, pp. 182-188, 2012.
51. J. Lowe, J. Araujo, J. Yang et al., "Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo," Experimental Eye Research, vol. 85, no. 4, pp. 425-430, 2007.
52. N. Ferrara, L. Damico, N. Shams, H. Lowman, and R. Kim, "Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration," Retina, vol. 26, no. 8, pp. 859-870, 2006.
53. R. Costa, Â. Carneiro, A. Rocha et al., "Bevacizumab and ranibizumab on microvascular endothelial cells: a comparative study," Journal of Cellular Biochemistry, vol. 108, no. 6, pp. 1410-1417, 2009.
54. Â. Carneiro, M. Falcão, A. Pirraco, P. Milheiro-Oliveira, F. Falcão-Reis, and R. Soares, "Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells," Experimental Eye Research, vol. 88, no. 3, pp. 522-527, 2009.
55. L. Yu, X. H. Liang, and N. Ferrara, "Comparing protein VEGF inhibitors: in vitro biological studies," Biochemical and Biophysical Research Communications, vol. 408, no. 2, pp. 276-281, 2011.
56. D. M. Brown, P. K. Kaiser, M. Michels et al., "Ranibizumab versus verteporfin for neovascular age-related macular degeneration," The New England Journal of Medicine, vol. 355, no. 14, pp. 1432-1444, 2006.
57. D. M. Brown, M. Michels, P. K. Kaiser, J. S. Heier, J. P. Sy, and T. Ianchulev, "Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: twoyear results of the ANCHOR study," Ophthalmology, vol. 116, no. 1, pp. 57.e5-65.e5, 2009.
58. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., "Ranibizumab for neovascular age-related macular degeneration," The New England Journal of Medicine, vol. 355, no. 14, pp. 1419-1431, 2006.
59. D. F. Martin, M. G. Maguire, S. L. Fine et al., "Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results," Ophthalmology, vol. 119, no. 7, pp. 1388-1398, 2012.
60. J. S. Heier, D. M. Brown, V. Chong et al., "Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration," Ophthalmology, vol. 119, no. 12, pp. 2537-2548, 2012.
61. E. S. Gragoudas, A. P. Adamis, E. T. Cunningham Jr., M. Feinsod, and D. R. Guyer, "Pegaptanib for neovascular agerelated macular degeneration," The New England Journal of Medicine, vol. 351, no. 27, pp. 2805-2816, 2004.
62. F. G. Holz, W. Amoaku, J. Donate et al., "Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular agerelated macular degeneration: the SUSTAIN study," Ophthalmology, vol. 118, no. 4, pp. 663-671, 2011.
63. K. Stieger, T. Cronin, J. Bennett, and F. Rolling, "Adenoassociated virus mediated gene therapy for retinal degenerative diseases," Methods in Molecular Biology, vol. 807, pp. 179-218, 2011.
64. P. A. Campochiaro, "Gene transfer for neovascular age-related macular degeneration," Human Gene Therapy, vol. 22, no. 5, pp. 523-529, 2011.
65. R. Zhou and R. R. Caspi, "Ocular immune privilege," F1000 Biology Reports, 2010.
66. F. Rolling, "Recombinant AAV-mediated gene transfer to the retina: gene therapy perspectives," Gene Therapy, vol. 11, no. 1, pp. S26-S32, 2004.
67. M. Weber, J. Rabinowitz, N. Provost et al., "Recombinant adenoassociated virus serotype 4 mediates unique and exclusive longterm transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery," Molecular Therapy, vol. 7, no. 6, pp. 774-781, 2003.
68. R. H. Smith, "Adeno-associated virus integration: virus versus vector," Gene Therapy, vol. 15, no. 11, pp. 817-822, 2008.
69. H.-C. Cheng, S.-I. Yeh, Y.-P. Tsao, and P.-C. Kuo, "Subconjunctival injection of recombinantAAV-angiostatin ameliorates alkali burn induced corneal angiogenesis," Molecular Vision, vol. 13, pp. 2344-2352, 2007.
70. M. Allocca, C. Mussolino, M. Garcia-Hoyos et al., "Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors," Journal of Virology, vol. 81, no. 20, pp. 11372-11380, 2007.
71. J. W. B. Bainbridge, M. H. Tan, and R. R. Ali, "Gene therapy progress and prospects: the eye," Gene Therapy, vol. 13, no. 16, pp. 1191-1197, 2006.
72. P. Challa, C. Luna, P. B. Liton et al., "Lentiviral mediated gene delivery to the anterior chamber of rodent eyes," Molecular Vision, vol. 11, pp. 425-430, 2005.
73. N. Loewen, D. A. Leske, J.D. Cameron et al., "Long-termretinal transgene expression with FIV versus adenoviral vectors," Molecular Vision, vol. 10, pp. 272-280, 2004.
74. R. P. Molina, H. Q. Ye, J. Brady et al., "A synthetic revindependent bovine immunodeficiency virus-based packaging construct," Human Gene Therapy, vol. 15, no. 9, pp. 865-877, 2004.
75. J. W. B. Bainbridge, C. Stephens, K. Parsley et al., "In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of cornealendothelium and retinal pigment epithelium," Gene Therapy, vol. 8, no. 21, pp. 1665-1668, 2001.
76. M. J. McConnell and M. J. Imperiale, "Biology of adenovirus and its use as a vector for gene therapy," Human Gene Therapy, vol. 15, no. 11, pp. 1022-1033, 2004.
77. R. Farjo, J. Skaggs, A. B. Quiambao, M. J. Cooper, and M. I. Naash, "Efficient non-viral ocular gene transfer with compacted DNA nanoparticles," PLoS ONE, vol. 1, no. 1, article e38, 2006.
78. T.W. Chalberg, H. L. Genise, D. Vollrath, and M.P. Calos, "φC31 integrase confers genomic integration and long-term transgene expression in rat retina," Investigative Ophthalmology and Visual Science, vol. 46, no. 6, pp. 2140-2146, 2005.
79. H. Viita, K. Kinnunen, E. Eriksson et al., "Intravitreal adenoviral 15-Lipoxygenase-1 gene transfer prevents vascular endothelial growth factor A-induced neovascularization in rabbit eyes," Human Gene Therapy, vol. 20, no. 12, pp. 1679-1686, 2009.
80. S.-J. Sheu, Y.-S. Bee, Y.-L. Ma et al., "Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin," Molecular Vision, vol. 15, pp. 1897-1905, 2009.
81. J. H. Distler, A. Hirth, M. Kurowska-Stolarska, R. E. Gay, S. Gay, and O. Distler, "Angiogenic and angiostatic factors in the molecular control of angiogenesis," Quarterly Journal of Nuclear Medicine, vol. 47, no. 3, pp. 149-161, 2003.
82. I. A. Bhutto, D. S. McLeod, T. Hasegawa et al., "Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration," Experimental Eye Research, vol. 82, no. 1, pp. 99-110, 2006.
83. I. A. Bhutto, S. Y. Kim, D. S. McLeod et al., "Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration," Investigative Ophthalmology and Visual Science, vol. 45, no. 5, pp. 1544-1552, 2004.
84. I. A. Bhutto, K. Uno, C. Merges, L. Zhang, D. S. McLeod, and G. A. Lutty, "Reduction of endogenous angiogenesis inhibitors in bruch'smembrane of the submacular region in eyes with agerelated macular degeneration," Archives of Ophthalmology, vol. 126, no. 5, pp. 670-678, 2008.
85. J. Tombran-Tink and C. J. Barnstable, "PEDF: a multifaceted neurotrophic factor," Nature Reviews Neuroscience, vol. 4, no. 8, pp. 628-636, 2003.
86. Y. Wang, P. Subramanian, D. Shen, J. Tuo, S. P. Becerra, and C. C. Chan, "Pigment epithelium-derived factor reduces apoptosis and pro-inflammatory cytokine gene expression in a murine model of focal retinal degeneration," ASN Neuro, vol. 5, no. 5, Article ID e00126, pp. 309-319, 2013.
87. J. Folkman, "Role of angiogenesis in tumor growth and metastasis," Seminars in Oncology, vol. 29, no. 6, supplement 16, pp. 15-18, 2002.
88. D. Hari, M. A. Beckett, V. P. Sukhatme et al., "Angiostatin induces mitotic cell death of proliferating endothelial cells," Molecular Cell Biology Research Communications, vol. 3, no. 5, pp. 277-282, 2000.
89. L. Claesson-Welsh, M. Welsh, N. Ito et al., "Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 10, pp. 5579-5583, 1998.
90. J. Spranger, H.-P. Hammes, K. T. Preissner, H. Schatz, and A. F. H. Pfeiffer, "Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: association with retinal photocoagulation," Diabetologia, vol. 43, no. 11, pp. 1404-1407, 2000.
91. T. Igarashi, K. Miyake, K. Kato et al., "Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in amurine proliferative retinopathymodel," Gene Therapy, vol. 10, no. 3, pp. 219-226, 2003.
92. T. A. Drixler, I. H. M. Borel Rinkes, E. D. Ritcbie et al., "Angiostatin inhibits pathological but not physiological retinal angiogenesis," Investigative Ophthalmology and Visual Science, vol. 42, no. 13, pp. 3325-3330, 2001.
93. T. Chavakis, A. Athanasopoulos, J.-S. Rhee et al., "Angiostatin is a novel anti-inflammatory factor by inhibiting leukocyte recruitment," Blood, vol. 105, no. 3, pp. 1036-1043, 2005.
94. K. Binley, P. S. Widdowson, M. Kelleher et al., "Safety and biodistribution of an equine infectious anemia virus-based gene therapy, retinostat, for age-related macular degeneration," Human Gene Therapy, vol. 23, no. 9, pp. 980-991, 2012.
95. J. Folkman, "Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action," Experimental Cell Research, vol. 312, no. 5, pp. 594-607, 2006.
96. Y.-M. Kim, S. Hwang, B.-J. Pyun et al., "Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1," The Journal of Biological Chemistry, vol. 277, no. 31, pp. 27872-27879, 2002.
97. Y.-J. Bai, L.-Z. Huang, A.-Y. Zhou, M. Zhao, W.-Z. Yu, and X.- X. Li, "Antiangiogenesis effects of endostatin in retinal neovascularization," Journal of Ocular Pharmacology and Therapeutics, vol. 29, no. 7, pp. 619-626, 2013.
98. K. Takahashi, Y. Saishin, R. L. Silva et al., "Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment," The FASEB Journal, vol. 17, no. 8, pp. 896-898, 2003.
99. A. Auricchio, K. C. Behling, A. M. Maguire et al., "Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents," Molecular Therapy, vol. 6, no. 4, pp. 490-494, 2002.
100. A. G. Marneros, D. R. Keene, U. Hansen et al., "Collagen XVIII/endostatin is essential for vision and retinal pigment epithelial function," The EMBO Journal, vol. 23, no. 1, pp. 89-99, 2004.
101. R. N. Fariss, S. S. Apte, B. R. Olsen, K. Iwata, and A.H. Milam, "Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye," The American Journal of Pathology, vol. 150, no. 1, pp. 323-328, 1997.
102. A. Janssen, J. Hoellenriegel, M. Fogarasi et al., "Abnormal vessel formation in the choroid of mice lacking tissue inhibitor of metalloprotease-3," Investigative Ophthalmology and Visual Science, vol. 49, no. 7, pp. 2812-2822, 2008.
103. J. H. Qi, Q. Ebrahem, N. Moore et al., "A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor- 2," Nature Medicine, vol. 9, no. 4, pp. 407-415, 2003.
104. R. Huegel, P. Velasco, M. de la Luz Sierra et al., "Novel antiinflammatory properties of the angiogenesis inhibitor vasostatin," Journal of Investigative Dermatology, vol. 127, no. 1, pp. 65-74, 2007.
105. D. Qin, T. Trenkwalder, S. Lee et al., "Early vessel destabilization mediated by angiopoietin-2 and subsequent vessel maturation via angiopoietin-1 induce functional neovasculature after ischemia," PLoS ONE, vol. 8, no. 4, Article ID e61831, 2013.
106. M. Felcht, R. Luck, A. Schering et al., "Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling," The Journal of Clinical Investigation, vol. 122, no. 6, pp. 1991-2005, 2012.
107. G. Gao, Y. Li, S. Gee et al., "Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium-derived factor. A possible mechanism for the antiangiogenic activity of plasminogen kringle 5," Journal of Biological Chemistry, vol. 277, no. 11, pp. 9492-9497, 2002.
108. Z. Zhang, J. X. Ma, G. Gao et al., "Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization," Investigative Ophthalmology and Visual Science, vol. 46, no. 11, pp. 4062-4071, 2005.
109. T.M. B. Nguyen, I. V. Subramanian, A. Kelekar, and S. Ramakrishnan, "Kringle 5 of human plasminogen, an angiogenesis inhibitor, induces both autophagy and apoptotic death in endothelial cells," Blood, vol. 109, no. 11, pp. 4793-4802, 2007.
110. S. X. Zhang, J. Sima, J. J. Wang, C. Shao, J. Fant, and J.-X. Ma, "Systemic and periocular deliveries of plasminogen kringle 5 reduce vascular leakage in rat models of oxygen-induced retinopathy and diabetes," Current Eye Research, vol. 30, no. 8, pp. 681-689, 2005.
111. J. Jin, K. K. Zhou, K. Park et al., "Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor," Investigative Ophthalmology & Visual Science, vol. 52, no. 9, pp. 6230-6237, 2011.
112. J. Lawler, "Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth," Journal of Cellular and Molecular Medicine, vol. 6, no. 1, pp. 1-12, 2002.
113. S. Wang, Z. Wu, C. M. Sorenson, J. Lawler, and N. Sheibani, "Thrombospondin-1-deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration," Developmental Dynamics, vol. 228, no. 4, pp. 630-642, 2003.
114. C. M. Sorenson, S. Wang, R. Gendron, H. Paradis, and N. Sheibani, "Thrombospondin-1 deficiency exacerbates the pathogenesis of diabetic retinopathy," Journal of Diabetes & Metabolism, supplement 12, 2013.
115. L. Contreras-Ruiz, B. Regenfuss, F. A. Mir, J. Kearns, and S. Masli, "Conjunctival inflammation in thrombospondin-1 deficient mouse model of Sjogren's syndrome," PLoS ONE, vol. 8, no. 9, Article ID e75937, 2013.